Transactions
3
Insider / BridgeBio Oncology Therapeutics, Inc.
Mehra Uneek
Chief Financial Officer at BridgeBio Oncology Therapeutics, Inc.
Mehra Uneek, Chief Financial Officer at BridgeBio Oncology Therapeutics, Inc., has disclosed 3 transactions in BBOT since March 12, 2026: 0 purchases (0 open-market buys) and 1 sale, worth about $4,732 at the reported prices. The latest was filed May 5, 2026, 34 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
1
Avg. disclosure lag
12.7d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Mehra Uneek made no purchases and 1 sale worth $5K, plus 2 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Mehra Uneek has traded 1 stock on record; the largest by dollars is BBOT.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 2 | 128,330 | — |
| F | Shares withheld for tax | 1 | 524 | $4,732 |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 3 | 0 | 1 · $4,732 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| BBOT | Sell F | April 1, 2026 | May 5, 2026 | 34d | 524 | $9 | $4,732 | late | Form 4 ↗ | |
| BBOT | Other A | March 10, 2026 | March 12, 2026 | 2d | 105,000 | — | — | derivative | Form 4 ↗ | |
| BBOT | Other A | March 10, 2026 | March 12, 2026 | 2d | 23,330 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 5, 2026 | Form 4 | 0001193125-26-207031 | 1 | published | EDGAR ↗ |
| March 12, 2026 | Form 4 | 0001193125-26-104384 | 2 | published | EDGAR ↗ |
Other insiders at BridgeBio Oncology Therapeutics, Inc.
- Kumar Neil Chief Executive Officer 158 rows
- MCCORMICK FRANK Director 9 rows
- Beltran Pedro Chief Scientific Officer 6 rows
- Ben Yong Chief Med & Dev Officer 5 rows
- Chen Bihua Director 5 rows
- Cobo Marc Principal Accounting Officer 5 rows
- Bauer Jake Director 3 rows
- Elmelech Idan COO & Principal Financial Ofcr 3 rows
- Wallace Eli M. Chief Executive Officer 3 rows
- Lebowitz Peter F Director 2 rows
Everyone on file, with contracts and lobbying under the company's name: BridgeBio Oncology Therapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 3 | March 12, 2026 | May 5, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.